Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Gastro Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Gastro Other
    Everolimus Is an Effective Treatment Option for Patients With Pancreatic Neuroendocrine Tumours: Presented at ESMO-GI - (DGDispatch)
    Proton Pump Inhibitors May Increase Risk for Clostridium difficile Outbreaks: Presented at ICC - (DGDispatch)
    Efficacy of Vaccination Against Traveller's Diarrhoea: Presented at ESPID - (DGDispatch)
    CT Colonography May Help High-Risk Patients Adhere to Follow-up Screening - (DGNews)
    Sevelamer Carbonate Approved in EU for Patients With Chronic Kidney Disease - (DGNews)

    News archive

     Recent webcasts/CME - Gastro Other
    • Biologics in Crohn's Disease: Treating Early, Treating Long-Term
    • Long-Term Sustainability Using Biologics in Crohn's Disease
    • Recent Updates in Crohn's Disease: Optimising Remission, Healing, and Quality of Life
    • Advances in the Management of Postoperative Ileus: Reducing the Clinical and Economic Burden
      Irritable Bowel Syndrome with Constipation (IBS-C): Improving Patient Care Assessment and Management

      Webcasts/CME archive

       Recent cases - Gastro Other
        An Unexpected Cause of Iron Deficiency Detected by Capsule Endoscopy
        Acute Abdominal Pain in a Patient Receiving Enoxaparin
        Splenic Rupture Following Colonoscopy, A Rare Complication
        Accurate Localization of Life Threatening Colonic Hemorrhage During Nuclear Medicine Bleeding Scan as an Aid to Selective Angiography
        Disabling Osteomalacia and Myopathy as the Only Presenting Features of Celiac Disease: A Case Report

        Cases archive
          




        my personal edition > gastro other > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Gallbladder Cancer Responds to Chemotherapy: Presented at ASCO-GI

        By Roberta Friedman, PhD

        SAN FRANCISCO, CA -- January 26, 2004 -- Chemotherapy can extend the life of patients with inoperable or metastasized cancer of the gallbladder, according to a study reported here January 24th at the First Annual Gastrointestinal Cancers Symposium, sponsored jointly by the American Society of Clinical Oncology and other societies.

        Study presenter José Reyes-Vidal, MD, Clinica Las Condes, Las Condes, Chile, said Chile has appreciable rates of gallbladder cancer, which is relatively rare elsewhere. It is the main cause of cancer mortality in Chilean women, Dr. Reyes-Vidal said, and "we expect it to increase in the next 10 years."

        Of 44 patients treated. 42 had at least a single course of chemotherapy, and the objective response rate was 48%. This included four patients who had a complete response.

        "Gallbladder cancer is responsive to chemotherapy," said Dr. Reyes-Vidal, "we can obtain a response in this very poor prognostic cancer, in almost 50% of our patients."

        Median survival was three or four times the historical rate of 73 days for untreated patients, he added. And, the patients had a "dramatic" improvement in quality of life, he said, "that was my clinical impression."

        The regimen was 1200 mg/m2 of gemcitabine and 35 mg/m2 of cisplatin on days 1 and 8, every 21 days for a total of six courses.

        Factors that put people in Chile at risk of gall bladder cancer include obesity and gallstones, especially stones bigger than 3 cm in diameter, Dr. Reyes-Vidal said. "We are studying what happens if we take these patients and perform cholecystectomy."

        Researchers in Chile are also considering if screening for gallstones would be cost effective, he said.


        [Study title: Gemcitabine (Gem) and cisplatin (CIS) in the treatment of patients (pts) with unresectable or metastatic gallbladder cancer. Results of the phase II GOCCHI study 2000-13. Abstract OP87]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send